The DCGI has approved Glenmark Pharmaceuticals' launch of antiviral drug Favipiravir which will be sold under the brand name FabiFlu.
The drug manufacturer said Favipiravir has shown clinical improvement of up to 88 percent in mild to moderate COVID-19 cases and offers a rapid reduction in viral load within four days. The drug has also been used in Russia, Japan, and China to treat COVID-19 patients and has proved successful, according to the company.
It can be used on patients with comorbid conditions such as diabetes and heart disease but is not recommended for those suffering from severe kidney or liver ailments, pregnant and lactating women.
FabiFlu tablets will be available for sale in hospitals and retail pharmacies across the country by early next week. It is to be administered under strict medical supervision and will not be available over-the-counter. It will be sold in a pack of 34 oral tablets of 200 mg each for ₹3,500 and the cost of the 14-day treatment will be an estimated ₹14,000.